A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapy (BOOG 2019-01 TIBET study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519204-27-00

Acronym

BOOG 2019-01

Enrollment

Registered

2024-11-15

Start date

2020-09-25

Completion date

Unknown

Last updated

2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced breast cancer

Brief summary

Percentage of patients being progression free at 8 weeks on trifluridine/tipiracil prescribed for ER-positive, HER2-negative advanced breast cancer patients previously treated with a taxane and capecitabine

Detailed description

Progression free survival, Response rate CR/PR at 16 weeks, Adverse Events, Quality of Life

Interventions

DRUGLonsurf 20 mg/8.19 mg film-coated tablets

DRUGLonsurf 15 mg/6.14 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients being progression free at 8 weeks on trifluridine/tipiracil prescribed for ER-positive, HER2-negative advanced breast cancer patients previously treated with a taxane and capecitabine	—

Secondary

Measure	Time frame
Progression free survival, Response rate CR/PR at 16 weeks, Adverse Events, Quality of Life	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026